DOCSLIB.ORG

DMG Vol 11 Ch 67: Prescribed Diseases

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
DMG Vol 11 Ch 67: Prescribed Diseases Chapter 67 - Prescribed diseases Contents Introduction General ........................................................................................................ 67001 Provision of NINO ......................................................................................... 67011 Adaption of legislation General ......................................................................................................... 67016 Burden of proof ............................................................................................. 67017 Benefits......................................................................................................... 67021 Relevant disease .......................................................................................... 67026 Disease contracted outside Great Britain ................................................ 67028 Claims and payments .............................................................................. 67029 Prescribed disease contracted by industrial accident ............................. 67031 Conditions resulting from prescribed diseases (sequelae) ..................... 67036 Questions arising on a prescribed disease claim .................................. 67041 Prescription Disease not prescribed ................................................................................. 67051 Prescribed occupations ........................................................................... 67056 Prescription of diseases involving poisoning etc .......................................... 67063 Diagnosis General ......................................................................................................... 67071 Determination of diagnosis question ............................................................ 67073 References for medical advice Non-respiratory diseases ........................................................................ 67076 Respiratory diseases ............................................................................... 67078 Power to dispense with reference for medical report .............................. 67080 Raising the diagnosis question afresh .................................................... 67086 Due to the nature of the employed earner’s employment ...................... 67091 Presumption ................................................................................................. 67101 Prescribed disease B5 ............................................................................ 67104 Prescribed diseases B1(b), B4(b), B7 and B8A ...................................... 67105 Vol 11 Amendment 46 June 2020 Prescribed disease A12 .......................................................................... 67106 Prescribed disease C23 .......................................................................... 67107 Prescribed disease D1 ............................................................................ 67108 Prescribed diseases for which there is no presumption .......................... 67109 When presumption continues to apply .................................................... 67110 When presumption does not apply .......................................................... 67111 Employment outside Great Britain ................................................................ 67131 European Economic Area countries ........................................................ 67132 Evidence ....................................................................................................... 67135 Date of onset, recrudescence and fresh contraction ............................ 67141 Determination of recrudescence question .................................................... 67156 Date of onset where workmen’s compensation received for the same disease ................................................................... 67161 Notes on individual diseases - general ................................................... 67181 Prescribed diseases A1, A2, A3, A4 and A7 Prescribed disease A1 before 30.3.17 ......................................................... 67191 Transitional provisions............................................................................. 67192 Prescribed disease A1 from 30.3.17 ............................................................ 67193 Reduced earnings allowance .................................................................. 67194 Prescribed disease A2 ................................................................................. 67201 Prescribed disease A3 ................................................................................. 67211 Reduced earnings allowance .................................................................. 67212 Prescribed disease A4 ................................................................................. 67216 Effect on REA .......................................................................................... 67219 Prescribed disease A7 ................................................................................. 67226 Effect on REA .......................................................................................... 67231 Prescribed disease A10 (occupational deafness) ................................... 67241 Time limits for claiming ................................................................................. 67243 Date of onset ........................................................................................... 67249 Prescription................................................................................................... 67256 Effect of current legislation ........................................................................... 67258 Obtaining and considering evidence ............................................................ 67260 Vol 11 Amendment 46 June 2020 Application of legislation ............................................................................... 67263 Degree of usage... ........................................................................................ 67271 Pneumatic .................................................................................................... 67272 Percussive .................................................................................................... 67273 Tools and machines ................................................................................ 67274 “Wholly or mainly” ........................................................................................ 67276 “Of the use of” .............................................................................................. 67281 “Whilst they are being so used” .................................................................... 67282 Immediate vicinity of ................................................................................ 67286 Immediate vicinity - equipment/claimant subject to movement ............... 67287 Prescribed occupation (a) Foundry, metalwork and associated industries ....................................... 67296 Cleaning, dressing and finishing ............................................................. 67299 On metal .................................................................................................. 67300 Air arc gouging ........................................................................................ 67302 Skid transfer bank ................................................................................... 67303 Knock out and shake out grids ................................................................ 67304 Machine (other than a power press machine) to forge metal .................. 67311 Forging .................................................................................................... 67312 Closed-die forging ................................................................................... 67313 Open-die forging ..................................................................................... 67315 Power press plant.................................................................................... 67317 Machine to cut, shape or clean metal nails ............................................. 67319 Plasma spray gun to spray molten metal ................................................ 67320 Prescribed occupation (b) Mining, Quarrying and Tunnelling ........................................................... 67326 Underground ........................................................................................... 67327 Mining coal .............................................................................................. 67328 Prescribed occupation (c) Concrete products ................................................................................... 67331 Prescribed occupation (d) The textile industry .................................................................................. 67332 Weaving .................................................................................................. 67333 Vol 11 Amendment 46 June 2020 High speed false twisting ........................................................................ 67334 The mechanical cleaning of bobbins ....................................................... 67338 Prescribed occupation (e) Woodworking and associated industries ................................................. 67341 Prescribed occupation (f) Water jetting and jet channelling ............................................................. 67343 Prescribed occupation (g) Engines in ships
Load more

Recommended publications
  • Ep001476158b1*
    (19) *EP001476158B1* (11) EP 1 476 158 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/455 (2006.01) A61P 29/00 (2006.01) 14.11.2007 Bulletin 2007/46 A61P 11/00 (2006.01) C07D 405/12 (2006.01) C07D 213/82 (2006.01) C07D 401/12 (2006.01) (2006.01) (21) Application number: 03739392.3 C07D 451/04 (22) Date of filing: 03.02.2003 (86) International application number: PCT/IB2003/000439 (87) International publication number: WO 2003/068235 (21.08.2003 Gazette 2003/34) (54) NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS NICOTINAMID-DERIVATE ALS PDE4-HEMMER DERIVES DE NICOTINAMIDE UTILES COMME INHIBITEURS DE PDE4 (84) Designated Contracting States: • HENDERSON, A.J., AT BE BG CH CY CZ DE DK EE ES FI FR GB GR c/o UK Patent Dept., HU IE IT LI LU MC NL PT SE SI SK TR Pfizer Ltd. Designated Extension States: Sandwich, Kent CT13 9NJ (GB) AL LT LV MK RO • MAGEE, T.V., c/o Pfizer Global Res. and Develop. (30) Priority: 11.02.2002 GB 0203196 Groton, CT 06340 (US) 10.09.2002 GB 0220999 • MARFAT, A., 21.10.2002 GB 0224453 c/o Pfizer Global Res. and Develop. 20.11.2002 GB 0227139 Groton, CT 06340 (US) • MATHIAS, J.P., (43) Date of publication of application: c/o Pfizer Global Res. and Develop. 17.11.2004 Bulletin 2004/47 Sandwich, Kent CT13 9NJ (GB) (73) Proprietors: • MCLEOD, D.G., • Pfizer Limited c/o Pfizer Global Res.
    [Show full text]
  • A Breathless Builder
    case presentations no03.qxd 17/05/2007 15:38 Page 2 CASE PRESENTATION A breathless builder J.J. Lyons1 P.J. Sime1 Case report hand-grinder, a common task known as "tuck- D. Ward2 The patient was a 30-year-old male mason whose pointing" (figure 2), while intermittently using a T. Watson3 work frequently involved cutting and grinding disposable particle mask. After completing this J.L. Abraham4 brick and cement with powered tools. He was an job, he felt well for ~2 months and then gradu- R. Evans5 active smoker (1–1.5 packs per day). He had ally began to develop a nonproductive cough, 6 M. Budev worked in building construction since the age of dyspnoea on exertion and an 11 kg weight loss K. Costas3 W.S. Beckett1 14 yrs, as a labourer then as a mason and had without fever. Serial pulmonary function testing been a mason for the previous 13 years. He showed restriction and a marked reduction in dif- reported frequent exposure to cement and brick fusing capacity. Chest computed tomography 1Division of Pulmonary and dust while removing stone floors with a jackham- (CT) showed bilateral diffuse infiltrates. A purified Critical Care Medicine, 2Dept of mer. From 8–2 months prior to presentation, he protein derivative test was negative. Anesthesiology and Biomedical had been employed repairing exterior brick on Bronchoalveolar lavage fluid was mucoid, and 3 Engineering and Division of three large apartment buildings (figure 1). This culture was negative. A transbronchial biopsy Thoracic/Foregut Surgery, University of Rochester, Rochester, required cutting through brick and mortar with a was nondiagnostic and the post-bronchoscopy 4Dept of Pathology, SUNY Upstate powered, high-speed demolition saw and grind- chest film showed a very small right apical pneu- Medical University, Syracuse, ing mortar from between bricks with a powered mothorax.
    [Show full text]
  • Respirable Crystalline Silica: Its History, Associated Disease, and the New OSHA Standard—Understanding the New Regulations
    Respirable Crystalline Silica: Its History, Associated Disease, and the New OSHA Standard—Understanding the New Regulations The Occupational Safety and Health Administration (OSHA) issued its new silica ruling on June 23, 2015 to take effect one year later. The new ruling (the Final Rule) allows industry from one to five years to comply with most requirements. The Construction Industry must comply by June 23, 2017, while Maritime and General Industry have until June 23, 2018. According to OSHA, the estimated impact of the new ruling translates to more than 600 lives saved and a reduction of more than 900 new cases of silicosis each year. The Final Rule is projected to provide net benefits of about $7.7 billion annually. There are, of course, opponents to this new regulation who deem the ruling requirements to be not only technologically and economically unfeasible, but also unnecessary. Opponents point to a Centers of Disease Control statistic which states that silica-related deaths have dropped by 93 percent from 1968 to 2007. They also believe OSHA’s cost estimate for implementation of the new rule is inaccurate and unrealistic. While OSHA projects the program to cost $511 million for companies to comply, opponents estimate the total costs will tally to nearly $5 billion.1 This paper covers: • Historical background of occupational silicosis • Industrial sources of silica exposures • Occupational illnesses caused by silica exposure • Comparison of the current regulation to the new regulation • Method to incorporate compliance practices
    [Show full text]
  • Rudys List of Archaic Medical Terms.Xlsm
    Rudy's List of Archaic Medical Terms A Glossary of Archaic Medical Terms, Diseases and Causes of Death. The Genealogist's Resource for Interpreting Causes of Death. Section 1 English Archaic Medical Terms Section 2 German / English Glossary Section 3 International / English Glossary www.antiquusmorbus.com Copying and printing is allowed for personal use only. Distribution or publishing of any kind is strictly prohibited. © 2005-2008 Antiquus Morbus, All Rights Reserved. This page left intentionally blank Rudy's List of Archaic Medical Terms A Glossary of Archaic Medical Terms, Diseases and Causes of Death. The Genealogist's Resource for Interpreting Causes of Death. Section 1 English Archaic Medical Terms Section 2 German / English Glossary Section 3 International / English Glossary www.antiquusmorbus.com Copying and printing is allowed for personal use only. Distribution or publishing of any kind is strictly prohibited. © 2005-2008 Antiquus Morbus, All Rights Reserved. This page left intentionally blank Table of Contents Section 1 Section 2 Section 3 EnglishGerman International Part 2 PAGE Part 4 PAGE Part 6 PAGE English A 5 German A 123 Croatian 153 English B 10 German B 124 Czech 154 English C 14 German C 127 Danish 155 English D 25 German D 127 Dutch 157 English E 29 German E 128 Finnish 159 English F 32 German F 129 French 161 English G 34 German G 130 Greek 166 English H 38 German H 131 Hungarian 167 English I 41 German I 133 Icelandic 169 English J 44 German J 133 Irish 170 English K 45 German K 133 Italian 170 English L 46 German
    [Show full text]
  • George Washington University Regulatory Studies Center
    Public Interest Comment1 on The Occupational Safety and Health Administration’s Proposed Standards for Occupational Exposure to Respirable Crystalline Silica Docket No. OSHA-2010-0034 RIN: 1218-AB70 December 4, 2013 Susan E. Dudley and Andrew P. Morriss2 The George Washington University Regulatory Studies Center The George Washington University Regulatory Studies Center works to improve regulatory policy through research, education, and outreach. As part of the Center’s mission, Center scholars conduct careful and independent analyses to assess rulemaking proposals from the perspective of the public interest. This comment on the Occupational Safety and Health Administration’s (OSHA) proposed standards for occupational exposure to respirable crystalline silica does not represent the views of any particular affected party or special interest, but is designed to evaluate the effect of OSHA’s proposal on overall social welfare. It builds on an article by the authors, “Defining What to Regulate: Silica & the Problem of Regulatory Categorization,”3 which we attach to this comment and respectfully submit for the record in this rulemaking. 1 This comment reflects the views of the authors, and does not represent an official position of the GW Regulatory Studies Center or the George Washington University. The Center’s policy on research integrity is available at http://research.columbian.gwu.edu/regulatorystudies/research/integrity. 2 Susan E. Dudley is director of the GW Regulatory Studies Center and research professor in the Trachtenberg School of Public Policy and Public Administration. Andrew P. Morriss is D. Paul Jones, Jr. & Charlene A. Jones Chairholder in Law and Professor of Business at the University of Alabama and a Research Scholar at the GW Regulatory Studies Center.
    [Show full text]
  • 数字 Accessory Bronchus 副気管支 Accessory Fissure 副葉間裂
    数字 accentuation 亢進 accessory 副の 数字 accessory bronchus 副気管支 accessory fissure 副葉間裂 10-ｙear survival 10年生存 accessory lobe 副肺葉 18F-fluorodeoxy glucose (FDG) 18F-フルオロデオキシグルコース accessory lung 副肺 2,3-diphosphoglycerate (2,3-DPG) 2,3ジフォスフォグリセレート accessory nasal sinus 副鼻腔 201TI (thallium-201) タリウム accessory trachea 副気管 5-fluorouracil（FU) 5-フルオロウラシル acclimation 順化 5-HT3 receptor antagonist 5-HT3レセプター拮抗薬 acclimation 馴化 5-hydroxytryptamine 5-ヒドロオキシトリプタミン acclimatization 気候順応 5-year survival 5年生存 acclimatization 順化 99mTc-macroaggregated albumin (99mTc-MAA) 99mTc標識大 acclimatization 馴化 凝集アルブミン accommodation 順応 accommodation 調節 accommodation to high altitude 高所順（適）応 A ACE polymorphism ACE遺伝子多型 acetone body アセトン体 abdomen 腹部 acetonuria アセトン尿［症］ abdominal 腹部［側］の acetylcholine(ACh) アセチルコリン abdominal breathing 腹式呼吸 acetylcholine receptor (AchR, AChR) アセチルコリン受容体（レセプ abdominal cavity 腹腔 ター） abdominal pressure 腹腔内圧 acetylcholinesterase (AchE, AChE) アセチルコリンエステラーゼ abdominal respiration 腹式呼吸 achalasia アカラシア abdominal wall reflex 腹壁反射 achalasia 弛緩不能症 abduction 外転 achalasia ［噴門］無弛緩［症］ aberrant 走性 achromatocyte (achromocyte) 無血色素［赤］血球 aberrant 迷入性 achromatocyte (achromocyte) 無へモグロビン［赤］血球 aberrant artery 迷入動脈 acid 酸 aberration 迷入 acid 酸性 ablation 剥離 acid base equilibrium 酸塩基平衡 abnormal breath sound(s) 異常呼吸音 acid fast 抗酸性の abortive 早産の acid fast bacillus 抗酸菌 abortive 頓挫性（型） acid-base 酸―塩基 abortive 不全型 acid-base balance 酸塩基平衡 abortive pneumonia 頓挫［性］肺炎 acid-base disturbance 酸塩基平衡異常 abrasion 剥離 acid-base equilibrium 酸塩基平衡 abscess 膿瘍 acid-base regulation 酸塩基調節 absolute
    [Show full text]
  • Redalyc.Acute Silicosis. an Infrequent Pneumoconiosis
    Revista Médica del Instituto Mexicano del Seguro Social ISSN: 0443-5117 [email protected] Instituto Mexicano del Seguro Social México Méndez-Vargas, María Martha; Soto-de la Fuente, Andrés Eduardo; Soto-Vera, Eduardo Andrés; Leo-Méndez, Rodolfo Acute silicosis. An infrequent pneumoconiosis Revista Médica del Instituto Mexicano del Seguro Social, vol. 53, núm. 4, julio-agosto, 2015, pp. 524-527 Instituto Mexicano del Seguro Social Distrito Federal, México Available in: http://www.redalyc.org/articulo.oa?id=457744938021 How to cite Complete issue Scientific Information System More information about this article Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Journal's homepage in redalyc.org Non-profit academic project, developed under the open access initiative Reportes breves Acute silicosis. An infrequent ilica is one of the most abundant materials in the earth’s crust as Clark proved in a study where he pneumoconiosis Sstates that 98.6 % of earth’s crust is composed by it. Accordingly, silicosis is the most frequent pneumo- coniosis in the world. This ailment is characterized by three different clinical forms that depend on the mag- nitude and therefore the percentage of free silica the María Martha Méndez-Vargas,a,c Andrés Eduardo Soto-de la Fuente,a,c workers are exposed to. Eduardo Andrés Soto-Vera,c,d Rodolfo Leo-Méndezb Type 1 or chronic is the most frequent, produced by exposition to free silica in 30 % concentrations. Type 2 or accelerated, is produced by expositions of 40 to 60 %. Type 3 or acute is produced when free silica contents go from 90 to 100 % concentrations.
    [Show full text]
  • Occupational Health: the Workplace
    Occupational Health: The Workplace KIONGO D Introduction • Other than the home environment, the workplace is the setting in which many people spend the largest proportion of their time.. • In favorable circumstances, work contributes to good health and economic achievements. • However, the work environment exposes many workers to health hazards that contribute to injuries, respiratory diseases, cancer, musculoskeletal disorders, reproductive disorders, cardiovascular diseases, mental and neurological illnesses, eye damage and hearing loss, as well as to communicable diseases. The workplace environment and economic development • In some of the least developed countries up to 80% of the workforce is employed in agriculture, mining and other types of primary production. • Heavy physical work, often combined with heat stress, occupational accidents, pesticide poisonings, organic dusts and biological hazards are thus the main causes of occupational morbidity and mortality in these countries. • Additionally, numerous non-occupational factors such as parasitic and infectious diseases, poor hygiene and sanitation, poor nutrition, general poverty and illiteracy aggravate these occupational health effects. • In rapidly-industrializing countries occupational health problems often arise due to use of technologies that are less advanced and more hazardous than those favored by developed countries. • Health and safety at work and the health of the work environment, as well as the external environment— can be difficult when technical and financial resources are limited, • In such circumstances, occupational accidents, traditional physical and ergonomic hazards, and occupational injuries diseases become major problems. • The true extent of the occupational morbidity is unknown, since many occupational injuries and diseases are neither notified nor registered. Workplace exposures Mechanical hazards, • unshielded machinery, unsafe structures in the workplace and dangerous tools are some of the most prevalent workplace hazards in developed and developing countries.
    [Show full text]
  • Future Medicine Through a New Pathology Antonietta M
    Clinical and Diagnostic Pathology Short Communication Future medicine through a new pathology Antonietta M. Gatti* Nanodiagnostics , Italy Even when an important advancement either in diagnostics, or supposed to be there.Just as an example, it is known for a very long in methods or in the technical equipment used has been achieved, time that there are lung diseases caused by physical (not chemical nowadays Medicine is going through a difficult period. and not biological) pathogens like, for instance, environmental dust. Among them silicosis, asbestosis, some sarcoidosis and, in general, The number of diseases to which there is no answer and no pneumoconiosis, cryptogenic granulomatosis, anthracosis, asbestosis, etiopathogenesis is known is increasing day by day, a condition bauxite fibrosis, byssinosis, chalicosis, siderosis, silicosis, stannosis, that implies that no clear and, what is more important, no correct talcosis. By means of Scanning Electron Microscopes equipped with diagnoses are issued, which, in turn, implies that no appropriate and an X-ray microprobe of an Energy Dispersive Spectroscope, we can see effective treatment is adopted. A “no diagnosis” means also that no and characterize by size, shape and chemistry the particulate matter prevention measures are applied. The list made available includes present in diseased tissues [1,2]. roughly 6,000-10,000 new rare diseases (the difference is due to the different organizations that perform the calculations), more and more The presence of non-biocompatible and non-biodegradable dust in often combined together as syndromes like, for instance and among pathological tissues testifies to the exposure the patient suffered, the many others, the Gulf-War and the Balkan Syndromes or the Chronic biological reaction that has resulted and the morphological cell changes Fatigue Syndrome or ASIA (Autoimmune/Inflammatory Syndrome).
    [Show full text]
  • Fused Nitrogen Containing Heterocycles And
    (19) TZZ ¥ZZ_T (11) EP 2 300 469 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 471/04 (2006.01) C07D 487/04 (2006.01) 24.06.2015 Bulletin 2015/26 A61K 31/4985 (2006.01) A61K 31/4353 (2006.01) A61P 37/00 (2006.01) (21) Application number: 09747213.8 (86) International application number: (22) Date of filing: 07.05.2009 PCT/US2009/043073 (87) International publication number: WO 2009/140128 (19.11.2009 Gazette 2009/47) (54) FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS KONDENSIERTE STICKSTOFF ENTHALTENDE HETEROZYKLEN SOWIE ZUSAMMENSETZUNGEN DAVON ZUR VERWENDUNG ALS KINASE INHIBITOREN HÉTÉROCYCLES CONDENSÉS AZOTÉS ET LEURS COMPOSITIONS COMME INHIBITEURS DE KINASE (84) Designated Contracting States: •FAN,Yi AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Poway HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL CA 92064 (US) PT RO SE SI SK TR • RUCKER, Paul, Vincent Designated Extension States: Carlsbad AL BA RS CA 92010 (US) • WANG, Zhicheng (30) Priority: 13.05.2008 US 52879 P San Diego 16.02.2009 US 152872 P CA 92130 (US) (43) Date of publication of application: (74) Representative: Bailey, Sam Rogerson et al 30.03.2011 Bulletin 2011/13 Mewburn Ellis LLP City Tower (73) Proprietor: Novartis AG 40 Basinghall Street 4056 Basel (CH) London EC2V 5DE (GB) (72) Inventors: (56) References cited: • ALBAUGH, Pamela, A. WO-A-01/00213 US-A1- 2007 093 490 Carlsbad CA 92009 (US) Remarks: • CHOI, Ha-Soon Thefile contains technical information submitted after San Diego the application was filed and not included in this CA 92128 (US) specification • CHOPIUK, Gregory Vancouver, Bristish Columbia V6G 1T9 (CA) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • ENCYCLOPEDIA of ALLERGIES Second Edition
    THE ENCYCLOPEDIA OF ALLERGIES Second Edition Myron A. Lipkowitz, R.P., M.D. Tova Navarra, B.A., R.N. The Encyclopedia of Allergies, Second Edition Copyright © 2001, 1994 by Myron A. Lipkowitz and Tova Navarra All rights reserved. No part of this book may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, or by any information storage or retrieval systems, without permission in writing from the publisher. For information contact: Facts On File, Inc. 11 Penn Plaza New York, NY 10001 Library of Congress Cataloging-in-Publication Data Lipkowitz, Myron A. Encyclopedia of allergies / Myron A. Lipkowitz, Tova Navarra.—2nd ed. p. cm.—(Library of health and living) Includes bibliographical references and index. ISBN 0-8160-4404-X (hc: alk. paper); ISBN 0-8160-4405-8 (pbk : alk. paper) 1. Allergy—Encyclopedias. I. Title: Allergies A–Z. II. Navarra, Tova. III. Title. IV. Series. RC585 .N38 2001 616.97’003—dc21 00-049490 Facts On File books are available at special discounts when purchased in bulk quantities for businesses, associations, institutions or sales promotions. Please call our Special Sales Department in New York at (212) 967-8800 or (800) 322-8755. You can find Facts On File on the World Wide Web at http://www.factsonfile.com Text and cover design by Cathy Rincon Printed in the United States of America VB FOF 10 9 8 7 6 5 4 3 2 1 This book is printed on acid-free paper. CONTENTS List of Tables iv Acknowledgments viii Preface ix History of Allergy and Immunology x Entries A–Z
    [Show full text]
  • United States Patent 19 11 Patent Number: 5,719,123 Morley Et Al
    USOO5719123A United States Patent 19 11 Patent Number: 5,719,123 Morley et al. 45) Date of Patent: Feb. 17, 1998 54 CICLOSPORINFORM FOR PULMONARY 56) References Cited ADMINISTRATION FOREIGN PATENT DOCUMENTS 75 Inventors: John Morley, Muttenz, Switzerland; 221 1848 12/1989 United Kingdom............. COTK 7/64 Andreas Rummelt, Lörrach, Germany; Martin List, Basel, Switzerland OTHER PUBLICATIONS 73) Assignee: Sandoz Ltd., Basel, Switzerland Dowling et al., Surgery, vol. 108, No. 2 (1990) PP 198-205. Primary Examiner-Howard E. Schain 21 Appl. No.: 254,094 Attorney, Agent, or Firm-Robert S. Honor; Melvyn M. 22 Filled: Jun. 6, 1994 Kassenoff; Thomas O. McGovern 57 ABSTRACT Related U.S. Application Data Pulmonary administration of Ciclosporin in orthorhombic 63 Continuation of Ser. No. 128,444, Sep. 28, 1993, abandoned, crystal form (designated "CY-AX-III"), e.g. for the treat which is a continuation of Ser. No. 852,597, Mar. 17, 1992, ment of obstructive or inflammatory airways disease, e.g. abandoned. asthma, as well as crystalline Ciclosporin, e.g. CY-A/X-III, 30 Foreign Application Priority Data in spheroidal particulate form, processes for its preparation and its pharmaceutical use, e.g. for pulmonary administra Mar 18, 1991 GB United Kingdom ................... 9105705 tion. Pharmaceutical compositions comprising CYA/X-III (51 nt C. m. A61K 38/13 and crystalline Ciclosporin, e.g. CY-AX-III, in spheroidal 52 U.S. Cl. ........................... 514/11: 514/15; 530/328; particulate form as well as Ciclosporin in solution in aerosol 53O?333 propellants are also provided. 58) Field of Search ........................ 514/15, 11; 530/328, 530/333 13 Claims, No Drawings 5,719,123 1.
    [Show full text]